Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
295 GBX | 0.00% | -8.67% | -16.31% |
Apr. 02 | MaxCyte inks deal with Be Bio; Orcadian firms farmout | AN |
Apr. 02 | MaxCyte, Inc. Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines | CI |
Financials (USD)
Sales 2024 * | 34.22M | Sales 2025 * | 45.52M | Capitalization | 387M |
---|---|---|---|---|---|
Net income 2024 * | -51M | Net income 2025 * | -45M | EV / Sales 2024 * | 6.25 x |
Net cash position 2024 * | 173M | Net cash position 2025 * | 143M | EV / Sales 2025 * | 5.37 x |
P/E ratio 2024 * |
-7.45
x | P/E ratio 2025 * |
-8.88
x | Employees | 143 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.02% |
Latest transcript on MaxCyte, Inc.
1 day | -1.32% | ||
1 week | -9.88% | ||
Current month | -15.01% | ||
1 month | -13.10% | ||
3 months | -27.22% | ||
6 months | +23.87% | ||
Current year | -17.42% |
Managers | Title | Age | Since |
---|---|---|---|
Maher Masoud
CEO | Chief Executive Officer | 49 | - |
Douglas Swirsky
DFI | Director of Finance/CFO | 54 | 23-03-26 |
James Brady
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick Balthrop
BRD | Director/Board Member | 67 | 22-11-30 |
Art Mandell
BRD | Director/Board Member | 71 | 06-04-30 |
Will Brooke
BRD | Director/Board Member | 68 | 04-02-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.20% | 12 M€ | -.--% | - | |
0.06% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 295 | 0.00% | 14 866 |
24-04-29 | 295 | 0.00% | 12,076 |
24-04-26 | 295 | 0.00% | 5,668 |
24-04-25 | 295 | -3.28% | 16,659 |
24-04-24 | 305 | -5.57% | 14,023 |
Delayed Quote London S.E., April 30, 2024 at 11:17 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.42% | 387M | |
+8.06% | 220B | |
+6.33% | 183B | |
+9.84% | 133B | |
+24.27% | 107B | |
-0.87% | 63.05B | |
+11.83% | 51.74B | |
+4.81% | 50.47B | |
-0.12% | 40.91B | |
+23.68% | 31.91B |
- Stock Market
- Equities
- MXCT Stock